探讨 COVID19 恢复期血浆疗效试验的可能性艺术。
The art of the possible in approaching efficacy trials for COVID19 convalescent plasma.
机构信息
North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
Faculty of Medicine and Medical Sciences, The University of Western Australia, Perth, Australia.
出版信息
Int J Infect Dis. 2021 Jan;102:244-246. doi: 10.1016/j.ijid.2020.10.074. Epub 2020 Oct 30.
Abstract
COVID-19 convalescent plasma (CCP) is widely used as a treatment. While safety data are enough, high-level evidences of efficacy are still missing. We summarize here the results from randomized controlled trials (RCT) published to date and analyze their flaws and biases. We then provide suggestions for next round of CCP RCTs, discussing specification of CCP, therapeutic dose, timing, control arm, disease stage, and outcome measures.
摘要
COVID-19 恢复期血浆（CCP）被广泛用作治疗方法。虽然安全性数据充足，但仍缺乏高等级的疗效证据。我们在这里总结了迄今为止发表的随机对照试验（RCT）的结果，并分析了它们的缺陷和偏差。然后，我们为下一轮 CCP RCT 提供了建议，讨论了 CCP 的具体规定、治疗剂量、时机、对照臂、疾病阶段和结果测量。
相似文献
1
The art of the possible in approaching efficacy trials for COVID19 convalescent plasma.
Int J Infect Dis. 2021 Jan;102:244-246. doi: 10.1016/j.ijid.2020.10.074. Epub 2020 Oct 30.
2
Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Trials. 2021 May 17;22(1):343. doi: 10.1186/s13063-021-05181-0.
3
Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial.
Trials. 2021 May 4;22(1):323. doi: 10.1186/s13063-021-05235-3.
4
Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Trials. 2021 May 17;22(1):342. doi: 10.1186/s13063-021-05189-6.
5
Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Trials. 2020 Jun 8;21(1):499. doi: 10.1186/s13063-020-04422-y.
6
Are convalescent plasma stocks collected during former COVID-19 waves still effective against current SARS-CoV-2 variants?
Vox Sang. 2022 May;117(5):641-646. doi: 10.1111/vox.13239. Epub 2022 Jan 12.
7
[Value of convalescent plasma in the therapy of COVID-19].
Dtsch Med Wochenschr. 2023 Mar;148(7):423-426. doi: 10.1055/a-2013-8775. Epub 2023 Mar 20.
8
COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial.
Microbiol Spectr. 2024 Jan 11;12(1):e0328623. doi: 10.1128/spectrum.03286-23. Epub 2023 Nov 27.
9
Reduced Mortality among COVID-19 ICU Patients after Treatment with HemoClear Convalescent Plasma in Suriname.
mBio. 2023 Apr 25;14(2):e0337922. doi: 10.1128/mbio.03379-22. Epub 2023 Feb 23.
10
Opportunities and Challenges of Observational Studies and Randomized Controlled Trials for Evaluating the Therapeutic Efficacy of COVID-19 Convalescent Plasma.
Cancer Invest. 2021 Jul-Aug;39(6-7):449-456. doi: 10.1080/07357907.2021.1942127. Epub 2021 Jul 5.
引用本文的文献
1
Systematic review and meta-analysis of randomised controlled trials testing the safety and efficacy of convalescent plasma in the treatment of coronavirus disease 2019 (COVID-19): Evidence-base for practise and implications for research.
Transfus Med. 2021 Dec;31(6):409-420. doi: 10.1111/tme.12803. Epub 2021 Jun 29.
2
Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing.
Heliyon. 2021 Apr;7(4):e06836. doi: 10.1016/j.heliyon.2021.e06836. Epub 2021 Apr 17.
3
Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor-recipient differences in concentration of neutralizing antibodies.
Clin Microbiol Infect. 2021 Jul;27(7):987-992. doi: 10.1016/j.cmi.2021.04.003. Epub 2021 Apr 17.
4
Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.
JMIR Public Health Surveill. 2021 Apr 7;7(4):e25500. doi: 10.2196/25500.
5
Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.
Rev Med Virol. 2021 Nov;31(6):e2231. doi: 10.1002/rmv.2231. Epub 2021 Mar 16.
6
The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19.
Life (Basel). 2021 Feb 15;11(2):144. doi: 10.3390/life11020144.
本文引用的文献
1
Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma.
Vox Sang. 2021 Jul;116(6):665-672. doi: 10.1111/vox.13056. Epub 2021 Mar 18.
2
Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial.
PLoS Med. 2021 Mar 3;18(3):e1003415. doi: 10.1371/journal.pmed.1003415. eCollection 2021 Mar.
3
Viral infection neutralization tests: A focus on severe acute respiratory syndrome-coronavirus-2 with implications for convalescent plasma therapy.
Rev Med Virol. 2021 Mar;31(2):e2170. doi: 10.1002/rmv.2170. Epub 2020 Sep 21.
4
Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG.
Am J Pathol. 2021 Jan;191(1):90-107. doi: 10.1016/j.ajpath.2020.10.008. Epub 2020 Nov 4.
5
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).
BMJ. 2020 Oct 22;371:m3939. doi: 10.1136/bmj.m3939.
6
What is the optimal usage of coronavirus disease 2019 convalescent plasma donations?
Clin Microbiol Infect. 2021 Feb;27(2):163-165. doi: 10.1016/j.cmi.2020.09.036. Epub 2020 Sep 29.
7
Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study.
Nat Med. 2020 Nov;26(11):1708-1713. doi: 10.1038/s41591-020-1088-9. Epub 2020 Sep 15.
8
Impact of convalescent and nonimmune plasma on mortality of patients with COVID-19: a potential role for antithrombin.
Clin Microbiol Infect. 2021 Apr;27(4):637-638. doi: 10.1016/j.cmi.2020.09.007. Epub 2020 Sep 9.
9
Convalescent plasma treatment for COVID-19: Tempering expectations with the influenza experience.
Eur J Immunol. 2020 Oct;50(10):1447-1453. doi: 10.1002/eji.202048723. Epub 2020 Sep 22.
10
Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients.
Mayo Clin Proc. 2020 Sep;95(9):1888-1897. doi: 10.1016/j.mayocp.2020.06.028. Epub 2020 Jul 19.
Zotero 插件